IMFINZI Specific-Clinical Experience Investigation in patients with NSCLC after definitive chemoradiation therapy

Study identifier:D4194C00003

ClinicalTrials.gov identifier:NCT03643484

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in patients with locally advanced unresectable non-small cell lung cancer who are treated with maintenance therapy after definitive chemoradiation therapy.

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

634

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 24 Oct 2018

Primary Completion Date: 30 Jun 2021

Study Completion Date: 30 Jun 2021

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2024 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Toshimitsu Tokimoto

AstraZeneca KK